Introduction
The vascular endothelium controls the contractile state of the underlying smooth muscle and thereby regulates vascular diameter and blood pressure. This control is achieved by the release of endothelial autacoids, nitric oxide (NO), prostaglandins, and a third mechanism, that induces hyperpolarization of the vascular smooth muscle and subsequent closure of voltage-gated calcium channels leading to a decrease in intracellular calcium and finally relaxation. Although it was initially assumed that this mechanism acts likewise through the release of a diffusible endothelial factor (endothelium-derived hyperpolarizing factor, EDHF) this view was later questioned by experiments demonstrating the involvement of gap junctions (Griffith et al., 2002; Dora et al., 2003; Mather et al., 2005; Chaytor et al., 2005; Sokoya et al., 2006) . These studies suggested that endothelial hyperpolarization is transferred from the endothelium to the smooth muscle by direct charge transfer through myoendothelial gap junctions [for in depth reviews see (de Wit and Wölfle, 2007; Feletou and Vanhoutte, 2009; Heberlein et al., 2009; Edwards et al., 2010; de Wit and Griffith, 2010; Garland et al., 2011)] . Whatever the exact mechanism is, endothelial hyperpolarization has been demonstrated to be crucial for the capability of agonists to induce EDH-type dilations in multiple studies.
Endothelial hyperpolarization following activation of GPCRs like muscarinergic (acetylcholine, ACh) receptors requires Ca 2+ -release from the ER. The resulting increase of intracellular Ca 2+ produces activation of Ca 2+ /calmodulin-regulated K + -channels (K Ca ) with intermediate (K Ca 3.1 or IK Ca ) and small conductance (K Ca 2.3 or SK Ca ). K Ca 3.1 is the predominant channel involved in ACh-induced EDH dilation in many vessels , while K Ca 2.3 channels are possibly responsible for flow-induced dilation and active hyperemia (Brähler et al., 2009; Milkau et al., 2010) . Importantly, both channels are voltageindependent and consequently do not inactivate during the ensuing hyperpolarization which 2012-BJP-1040-RP.R2
-5 -renders them an attractive target to induce a sustained, solid hyperpolarization towards the K + -equilibrium potential. Confirming a pivotal role of K Ca 3.1 channels, genetic deficiency of K Ca 3.1 in mice abrogates ACh-induced EDH-type vasodilation in large conduit arteries and in the cremaster microcirculation in vivo and -at the systemic level -results in mild systolic hypertension . Intriguingly, pharmacological activation of this channel by the K Ca 3.1/K Ca 2 activator naphtho[1,2-d]-2-ylamine (SKA-31), a compound with a ten-fold higher potency for K Ca 3.1 than K Ca 2.3 lowers blood pressure in normotensive mice in a K Ca 3.1-dependent fashion as well as in a murine model of short-term angiotensin-II induced hypertension (Sankaranarayanan et al., 2009) . Recently, intravenous injection of SKA-31 has also been shown to transiently lower pressure in conscious dogs (Damkjaer et al., 2012) . In addition to nitric oxide, K Ca 3.1 (and K Ca 2.3) channels accordingly constitute promising novel pharmacological targets for lowering peripheral vascular resistance in hypertension or ischemic heart disease.
However, it is not clear whether pharmacological activation of K Ca 3.1 produces vasodilation of arterioles and thereby elicits a depressor response and whether myoendothelial gap junctions are involved in such dilations, in analogy to the suggested role of gap junctions in EDH-type dilations upon stimulation with ACh. Gap junctions are clusters of intercellular channels composed of connexin proteins. Six connexins oligomerize into a hemichannel in the plasma membrane, which docks to its counterpart in the adjacent cell to form an intercellular channel. Of the four connexins expressed in vascular cells, connexin40 (Cx40) connects endothelial cells homocellularly (de Wit, 2004) and is reportedly also an essential component in myoendothelial gap junctions (Isakson and Duling, 2005; Isakson et al., 2006; Isakson et al., 2008) . Recently, we confirmed a role for Cx40-dependent myoendothelial coupling in ACh-induced EDH-dilations in an isometric experimental setting in vitro, whereas in vivo Cx40 seemed dispensable for EDH-type dilations in small arteries (Boettcher and de Wit, 2012 -BJP-1040 -RP.R2 -6 -2011 . Therefore, we hypothesized, that activation of K Ca 3.1 induces dilations in resistancesized arterioles and lowers arterial pressure in the intact animal and that these effects aresimilar to ACh-induced responses -independent of Cx40. To test this hypothesis, we studied vascular responses elicited by SKA-31 in mice ubiquitously deficient for Cx40 as well as in animals that lacked Cx40 only in endothelial cells. Global Cx40-deficient mice are hypertensive (de Wit et al., 2000; due to enhanced secretion of renin and activation of the renin-angiotensin-aldosterone system (Wagner et al., 2007; Wagner et al., 2010) , while endothelial-specific Cx40-deficient mice are normotensive (Wagner et al., 2010; Chadjichristos et al., 2010) . Thus, our approach also allowed us to study the effect of pharmacological K Ca 3.1 activation in a chronic renin-dependent, severe hypertension model.
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Methods
Animals:
Animal care and experiments were in accordance with the German Animal Welfare Act and approved by local authorities. Mice mice with endothelium-specific Cx40 deficiency (Cx40 fl/fl :Tie2-Cre) carrying a Cre-recombinase under the control of the Tie2 promoter and homozygously the floxed Cx40 gene (Cx40 fl ) were generated (Wagner et al., 2010) .
Littermates without Cre-recombinase served as controls (Cx40
, and wild-type control littermates were derived from our breeding colonies.
Endothelial cell isolation and measurements of membrane potential:
Endothelial cells were isolated from the carotid artery and measured as described (Brähler et al., 2009) . SKA-31 (1 µmol/L) was added to the bath solution followed by adding the selective K Ca 3.1 blocker TRAM-34 (1 µmol/L) and the K Ca 2.X blocker UCL1684 (1 µmol/L) . Drugs did not modulate inter-endothelial electrical coupling as capacitance values remained unchanged. Electrical uncoupling was achieved by addition of 10 µmol/L docosahexaenoic acid .
Intravital microscopy of the microcirculation:
Mice were anesthetized with intraperitoneal injection of fentanyl, midazolam, and medetomidin followed by intravenous infusion. The cremaster muscle was prepared as described . Arteriolar diameters were measured before and during superfusion 
Blood pressure measurement:
Mice were anesthetized by inhalation of isoflurane (2%) and received fentanyl (0.07 mg/kg intraperitoneally) for implantation of telemetric pressure transducers (Data Sciences
International, s'Hertogenbosch, Netherlands). SKA-31 was dissolved in peanut oil and administered intraperitoneally. Measurements were started 30 min before application and continued thereafter. Increasing concentrations of SKA-31 (1-100 mg/kg) were studied in all animals nonrecurringly during consecutive nights.
Statistics and calculations:
Data within groups were compared using paired t-tests and between different groups by analysis of variance (one-way ANOVA) followed by the Bonferroni post hoc test. Time series measurements (pressure, heart rate) were analysed by univariate repeated measures ANOVA to test the hypothesis of a constant mean over time. The repeated measures ANOVA was also used to test whether curves differed between genotypes. Normal distribution of the residuals was validated using Q-Q plots. Differences were considered significant at a corrected error probability of P<0.05. Data are given as mean±SEM.
For further details on experimental methods see supplement.
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-9 - (Wölfle et al., 2009) . Local superfusion of SKA-31 over the cremaster muscle induced a concentration-dependent dilation in wt arterioles that was significantly larger than the subtle diameter changes triggered by superfusing the solvent (cremophor) alone ( dilations that were significantly stronger than dilations induced by ACh alone suggesting an additive effect of these dilators except for the highest concentrations of ACh used (Fig.S1 ).
Results
SKA
SKA-31 induced arteriolar dilations do not require endothelial Cx40
In the next series of experiments, we used mice lacking Cx40 in endothelial cells were excluded from further analysis. The remaining arterioles (n=16) dilated in response to
Cbx from 12±6 to 16±7 µm (P<0.001). However, SKA-31-induced dilations remained unaffected ( Fig.S2 ) indicating that these dilation were independent of gap junctional coupling.
Likewise, dilations upon ACh and sodium-nitroprusside were not attenuated (3 µmol/L, not shown).
SKA-31 hyperpolarizes endothelial cell clusters
We next studied the hyperpolarizing efficacy of SKA-31 in isolated endothelial cell clusters : 10±1 pF) corresponding to single murine endothelial cells Intraperitoneal injection of SKA-31 at all dosages as well as injection of the vehicle induced a slight increase in pressure (Fig.4) and a transient increase in heart rate in all genotypes (Fig.5 , Fig.6B ) that most likely reflects excitement and sympathetic activation upon animal handling.
At 1 and 3 mg/kg, SKA-31 did not produce a significant change from MAP baseline in any genotype (Fig.4) . SKA-31 was also without significant effect at 10 mg/kg in WT or by 30±11 mmHg in Cx40 -/-animals (P=0.45 between genotypes) as assessed from individual pressure curves. At 100 mg/kg SKA-31 induced a more prolonged pressure drop that was similar in all genotypes and lasted for up to 120 min after injection (Fig.4, Fig.6A ). The (Fig.5, Fig.6B ). (Simon and McWhorter, 2003; it is therefore questionable whether EDH-type dilations in vivo do indeed require myoendothelial gap junctions as in vitro studies have suggested (Mather et al., 2005) .
SKA-31 activates K Ca 3.1 channels with an EC 50 value of 0.26 µmol/L and K Ca 2.3 channels with a ten-fold lower potency (2.9 µmol/L). In the murine vasculature, both channels are selectively expressed in endothelial cells (Brähler et al., 2009; Potocnik et al., 2009) -15 - (Sankaranarayanan et al., 2009; Damkjaer et al., 2012) . However, in these vessels SKA-31
was not a vasodilator in its own right. Herein, we provide the first evidence that SKA-31 per se is capable of dilating resistance vessels in skeletal muscle. This arteriolar dilation is strictly K Ca 3.1-dependent since it was absent in K Ca 3.1 -/-mice. The SKA-31 mediated dilation was potent, amounting to about 40% of the vessel's maximal diameter, but did not reach the maximal levels achieved by ACh stimulation (range of 75%) (Koeppen et al., 2004; Wölfle and de Wit, 2005) . This lower efficacy for SKA-31 may be due to its limited access to the endothelial cells when applied with the superfusion solution onto the cremaster muscle and may also explain the need for higher concentrations compared to the reported EC 50 values of 0.26 µmol/L determined by measuring channel activity in transfected HEK293 cells or isolated endothelial cells. The SKA-31 induced dilation is of a similar magnitude as those reported for the less selective activator of K Ca activator DCEBIO which also induces dilations in a K Ca 3.1-dependent manner (Wölfle et al., 2009) . The present experiments demonstrate that the SKA-31-initiated response does not require NO or prostaglandins and that it therefore can be deemed a pure EDH-type dilation (Fig.1) . Nonetheless, it may well be, that SKA-31 increases NO production as reported for rat arteries (Sheng et al., 2009; Stankevicius et al., 2011) . However, if so, this does not seem to contribute to the dilation in murine arterioles in the in vivo experiments presented here as is true for stimulation using ACh (Koeppen et al., 2004) .
The combined application of SKA-31 and ACh induced additive effects evident at lower but not at higher concentrations at which a solid hyperpolarization to near the K + equilibrium limits the dilator response. Despite the effects being mainly additive, SKA-31 may still restore endothelial function in situations of impaired ACh-dilation Kohler et al., 2010) or in case of an upregulated K Ca 3.1-mediated pathway (Simonet et al., 2012) because SKA-31 potentiated ACh-induced dilations also in other species or vascular beds without 2012-BJP-1040-RP.R2
-16 -exhibiting a dilator effect in itself (Sankaranarayanan et al., 2009; Damkjaer et al., 2012) .
From a more methodological perspective, SKA-31's efficacy at producing arteriolar dilation without the need to stimulate G-protein coupled receptors may render it a novel pharmacological tool to investigate pure EDH-type dilations and related electrical mechanisms of dilation such as direct charge transfer through myoendothelial coupling involving Cx40 as reported for rat small mesenteric arteries (Mather et al., 2005) .
A major aim of the present study was to determine whether Cx40 is required for K Ca 3.1-mediated arteriolar dilations. Our results clearly show that arteriolar dilations induced by SKA-31 were not attenuated in mice lacking Cx40 in endothelial cells. We therefore conclude that K Ca 3.1-mediated endothelial hyperpolarization per se is able to induce dilation even in the absence of endothelial Cx40 thus excluding that Cx40-dependent myoendothelial gap junctions are a prerequisite for K Ca 3.1-mediated (resembling EDH-type) dilations in murine skeletal muscle arterioles as was reported for rat mesenteric vessels (Mather et al., 2005) . We further suggest that EDH-type dilations may be even completely independent of myoendothelial gap junctions, since Cx40-deficient endothelial cells also exhibit strongly reduced Cx37 expression (Simon and McWhorter, 2003; . In fact, we demonstrate herein for the first time a substantial impairment of electrical coupling in endothelial cell clusters derived from Cx40 -/-carotid arteries (Fig.3C) . The fact that the nonspecific gap junction blocker carbenoxolone did not affect SKA-31 dilations supports further the idea that these dilations do not require gap junctional coupling. This conclusion is also corroborated by our previous observations in Cx40-deficient animals which exhibit intact ACh-induced EDH-type dilations in the in vivo setting (de Boettcher and de Wit, 2011) . We therefore suggest that other mechanisms than the mere transmission of an endothelial hyperpolarization towards the vascular smooth muscle need to be reevaluated to explain EDH-type dilator responses at least in murine skeletal arterioles.
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-17 -Intraperitoneal injections of SKA-31 has been previously reported to lower 24h mean arterial pressure by approximately 5 mmHg in normotensive mice and by about 12 mmHg in angiotensin-II infused hypertensive mice, which requires the presence of K Ca 3.1 (Sankaranarayanan et al., 2009) , while intravenous SKA-31 produced an immediate and strong but transient depressor response in conscious dogs (Damkjaer et al., 2012) . In the present study, we provide further insights about the time course of SKA-31´s systemic cardiovascular actions. Administration of 30 and 100 mg/kg SKA-31 lowered pressure by 20 to 32 mmHg within 2h after intraperitoneal injection in normo-and hypertensive genotypes.
Lower concentrations of 1 and 3 mg/kg had no effect, while 10 mg/kg only produced a depressor response in hypertensive Cx40-deficient mice. Most likely, these depressor responses were elicited by a decrease of peripheral resistance due to dilation of arterioles as observed in the microcirculation. The time course of the SKA-31 effects is compatible with reported plasma concentrations of SKA-31 which peak 2h after a single intraperitoneal injection (Sankaranarayanan et al., 2009 ). The pressure drop was not accompanied by significant changes in heart rate in wild-type mice at 30 mg/kg SKA-31 suggesting that neither the pressure drop was due to a change in heart rate nor that the return to baseline is driven predominantly by a reflective increase in heart rate. In fact, unlike dogs (Damkjaer et al., 2012) , mice seem to lack reflex tachycardia to SKA-31-induced depressor responses.
However, other slow counterbalancing regulatory effects may have possibly offset a more prolonged reduction in pressure, e.g. an increase in stroke volume or other humoral mechanisms such as increased catecholamine secretion or activation of the renin-angiotensinaldosterone system.
In normotensive endothelial-cell specific Cx40-deficient animals, SKA-31 induced a comparable decrease in arterial pressure starting at a dose of 30 mg/kg without a drop in heart 2012-BJP-1040-RP.R2
-18 -rate. In fact, heart rate was moderately enhanced in this group. Hypertensive ubiquitous Cx40-deficient mice responded in a similar fashion to 30 mg/kg and even at 10 mg/kg without changes in heart rate. Thus, SKA-31 decreases blood pressure independently of endothelial Cx40 and, most interestingly, is also effective in a model of chronic hypertension related to a renin excess and chronic activation of the renin-angiotensin-aldosterone system (de Wagner et al., 2007; Schweda et al., 2009 ).
Higher concentrations of SKA-31 (100 mg/kg) exerted a strong and long-lasting depressor response but this was accompanied by a significant slowing of heart rate. To our knowledge K Ca 3.1-channels are not expressed in sinus node cells or pacemaker tissue and are not implicated in pacemaker functions. However, mRNA encoding for K Ca 2 channels has been identified in cardiac atrial and ventricular myocytes (Tuteja et al., 2010) . Accordingly, cardiac overexpression of K Ca 2.2 shortened the action potential in pacemaker tissue and enhanced firing rate and, conversely, its ablation decreased spontaneous firing (Zhang et al., 2008) suggesting that K Ca 2 channel modulation may affect electrical behaviour in pacemaker tissue.
Overexpressed K Ca 2 is still responsive to physiological regulation and consequences are different from phramacological channel activation. Although speculative, the potentiated activity of K Ca 2 channels by SKA-31 may keep the pacemaker tissue in a hyperpolarized state that leaves pacemaker cells further away from the threshold to fire an action potential and, ultimately, decrease heart rate. Additionally, a central sedative effect with a resulting decrease of sympathetic drive may add to the slowing of the heart rate. K Ca 2 channels underlie the medium afterhyperpolarization in neurons and SKA-31 is brain penetrant. In fact, SKA-31 exerts a sedative effect at higher doses independent of K Ca 3.1 since it was also observed in animals deficient for K Ca 3.1 (Lambertsen et al., 2012) . Thus, we suggest that the bradykardia observed at the highest SKA-31 dose in mice is likely due to activation of K Ca 2 channels through an effect on pacemaker tissue in conjunction with a potential sedative effect.
-19 -However, telemetric pulse wave recordings as conducted in the present study cannot resolve these questions, but our findings highlight the fact that specific activation of K Ca 3.1 is desirable to induce dilation and pressure decrease.
In conclusion, the endothelial K Ca 3.1 channel provides an attractive pharmacological target to initiate EDH-type dilations. Upon activation, endothelial cells hyperpolarize and induce an arteriolar dilation that is independent of NO and prostaglandins. In vivo, this dilation surprisingly does not require the presence of Cx40 in endothelial cells suggesting that in arterioles myoendothelial gap junctions either do not transfer the hyperpolarization from the endothelium to the underlying smooth muscle or that they do so without the need for Cx40.
The fact that K Ca 3.1 activation can still induce EDH-type dilations and lower pressure in Cx40-deficient mice, which exhibit severe chronic renin-dependent hypertension, suggests that K Ca 3.1 activators like SKA-31 should be evaluated as novel treatment options for severe renal hypertension. 
Methods
Animals:
Animal care and experiments were in accordance with the German Animal Welfare Act and approved by local authorities and are described in accordance with the ARRIVE guidelines.
Mice ), and wild-type control littermates were derived from our breeding colonies and genotyped as described previously . Overall, 63 mice were studied.
Endothelial cell isolation and measurements of membrane potential:
Endothelial cells were isolated from the carotid artery and measured as described (Brähler et al., 2009; . After dissection, mounting, and incubation of the arteries with trypsin, endothelial cells, mainly as cell clusters (8±4 cells, range: 3-21), were detached by gentle scrapping and transferred to a culture dish containing DMEM medium and cover slips to allow settling (2-4 h). After establishing electrical access by seal rupture, we measured membrane capacitance in cell clusters using an Axopatch patch-clamp amplifier (Axon Instruments, Foster City, CA) and recorded thereafter membrane potential in the current-clamp. Recordings were stable for 3-10 min. To activate K Ca -channels, SKA-31 (1 µmol/L) was added to the bath solution followed by adding the selective K Ca 3.1 blocker TRAM-34 (1 µmol/L) and the K Ca 2.X blocker UCL1684 (1 µmol/L) . Drugs did not modulate inter-endothelial electrical coupling as capacitance values remained unchanged. Electrical uncoupling was achieved by addition of
Blood pressure measurement:
Mice were anesthetized by inhalation of isoflurane (2% in oxygen) and received fentanyl (0.07 mg/kg intraperitoneally for pain relief) for implantation of telemetric pressure transducers (Data Sciences International, s'Hertogenbosch, Netherlands). The catheter was introduced into the left carotid artery and the transmitter positioned subcutaneously at the abdomen . The animals recovered for 5 days before measurements were started. SKA-31 was dissolved in warmed (37°C) peanut oil by vigorous stirring and administered intraperitoneally (150 µL) at 7 pm. Measurements were started 30 min before application and continued thereafter. Increasing concentrations of SKA-31 (1-100 mg/kg) were studied in all animals nonrecurringly during consecutive nights with a 48 h interval between applications of higher SKA-31 concentrations. Finally, mice were sacrificed following an overdose of pentobarbital. Data were analyzed using DSI software. µmol/L). n=16 arterioles in 5 mice, arterioles that exhibited a very low resting tone (i.e. ratio of resting to maximal diameter >0.8, n=24) in the presence of Cbx were excluded from analysis.
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Figure S1
Acetylcholine (ACh) induced a concentration dependent dilation during inhibition of NOsynthase and cyclooxygenase (LN and Indo, 3 and 30 µmol/L) in arterioles of wild-type mice. SKA-31 applied alone dilated these arterioles by 8±3% (3 µmol/L) and 38±5% (30 µmol/L). Combined application of ACh and SKA-31 (A: 3 µmol/L; B: 30 µmol/L) induced a significantly stronger dilation that was comparable to the sum of the dilations initiated by each substance alone (expected dilation, dashed line) with the exception of high ACh concentrations. A: n=57 to 65 arterioles in 7 mice, B: n=24 arterioles in 3 mice; *: P<0.05, **: P<0.01, ***: P<0.001 vs. control. SKA-31 induced a concentration dependent dilation during inhibition of NO-synthase and cyclooxygenase (LN and Indo, 3 and 30 µmol/L) in arterioles of wild-type mice that was unaffected in the presence of the nonspecific gap junction blocker carbenoxolone (Cbx, 30 µmol/L). n=16 arterioles in 5 mice, arterioles that exhibited a very low resting tone (i.e. ratio of resting to maximal diameter >0.8, n=24) in the presence of Cbx were excluded from analysis. 
